The impact of rare cancer and early-line treatments on the benefit of comprehensive genome profiling-based precision...

Area of Science:

• Oncology
• Genomics
• Personalized Medicine

Background:

• Comprehensive genome profiling (CGP) is crucial for guiding genomically matched therapies in cancer patients.
• The impact of cancer type and treatment timing on CGP's therapeutic benefit requires further investigation.

Purpose of the Study:

• To evaluate the benefit of CGP based on cancer type and treatment timing.
• To identify factors influencing therapeutic response to CGP-guided treatments.

Main Methods:

• A pan-cancer prospective study (TOP-GEAR) involving 507 patients with advanced solid tumors.
• Genotyping using a single CGP test, followed by a median 590-day follow-up.
• Assessment of therapeutic response using progression-free survival (PFS) and overall response rate (ORR).

Main Results:

• 12.2% of patients received matched therapies with a 32.3% ORR.
• Rare cancer patients had a lower proportion receiving matched therapies but a higher ORR (43.8%) compared to non-rare cancers (20.0%).
• Early-line treatments (1st/2nd line) post-CGP showed higher ORR (62.5%) than later lines (21.7%).

Conclusions:

• Patients with rare cancers significantly benefit from CGP, experiencing increased therapeutic response.
• Early-line treatment following CGP enhances therapeutic benefits, regardless of cancer type.
• Rare cancer status and early treatment initiation are independent predictors of positive therapeutic response to matched therapies.